艾芦库单抗
化合物
艾芦库单抗（INN：Icrucumab；开发代号：IMC-18F1）是一种人单克隆抗体，设计用于治疗实体瘤。[1][2]艾芦库单抗由ImClone Systems公司开发，正在进行I期试验。[3]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | VEGFR-1 |
| 臨床資料 | |
| 其他名稱 | IMC-18F1 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1024603-92-6  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6514H10024N1756O2032S42 |
| 摩尔质量 | 146,796.63 g·mol−1 |
参考资料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab (PDF). American Medical Association. [2024-01-21]. （原始内容存档 (PDF)于2012-09-28）.
- ^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. April 2014, 32 (2): 303–11. PMID 23903897. S2CID 34756277. doi:10.1007/s10637-013-9998-8.
- ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov